Notable Briefs for IBD -December 2016

MI Abdalla et al. Inflamm Bowel Dis 2016; 22: 2658-64.  This article reviewed the impact of an ostomy on QOL (quality of life) for Crohn’s disease patients. n=402 with ostomy compared with 4331 CD patients without.

Key findings:

  • Patients with ostomy were more likely to be in remission: 48.5% versus 31.35%.
  • Having an ostomy did not impact overall health-related quality of life but did reduce social role satisfaction.
  • Conclusion: “ostomy is well tolerated…particularly when clinical remission is achieved.”

WKM Liew et al. J Pediatr 2016; 178: 227-32. In this study with 16 patients (aged 6-24 years) who received thalidomide, more information on neuropathy is provided.  “All subjects with cumulative doses greater than 60 g developed polyneuropathy.”  4 of 5 subjects receiving the drug for >20 months developed neuropathy. Two important points:

V Collij et al. Inflamm Bowel Dis; 2016; 22: 2562-70. “We identified drugs that target the proteins encoded by IBD candidate genes.” Key finding: There were 113 drugs that could potentially be used in IBD treatment, including 14 known IBD drugs, 48 drugs that are/have been tested for IBD, 19 being tested for other inflammatory diseases, and 32 new investigational medications.

from one of the best days all year

from one of the best days all year on board “Bufflehead”